DEXA/CT, dual-energy X-ray absorptiometry/computed tomography
Outcomes from the Phase 3 SURMOUNT-1 study show adults with prediabetes and obesity or overweight who received tirzepatide had a 94% reduction in the risk of progression to Type 2 diabetes
Its important to remember: These results are averages
What Guidelines Say About Supplement Co-prescribing The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states that "the use of dietary supplements alongside approved anti-obesity medications should be evaluated for additive physiological effects, particularly those affecting glucose or cardiovascular parameters" [21]
Novo will have a nice heads up on the manufacturing challenge because it already markets Rybelsus, which became the first oral treatment for type 2 diabetes when it received FDA approval in 2019
Enkhbaatar P, Pruitt BA, Suman O, et al